We investigated whether the newly developed antibody (Ab) -targeted therapy inotuzumab ozogamicin (CMC-544), consisting of a humanized CD22 Ab linked to calicheamicin, is effective in pediatric primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells in vitro, and analyzed which parameters determine its efficacy. CMC-544 induced dose-dependent cell kill in the majority of BCP-ALL cells, although IC 50 values varied substantially (median 4.8 ng/ml, range 0.1-1000 ng/ml at 48 h). The efficacy of CMC-544 was highly dependent on calicheamicin sensitivity and CD22/CMC-544 internalization capacity of BCP-ALL cells, but hardly on basal and renewed CD22 expression. Although CD22 expression was essential for uptake of CMC-544, a repetitive loop of CD22 saturation, CD22/CMC-544 internalization and renewed CD22 expression was not required to achieve intracellular threshold levels of calicheamicin sufficient for efficient CMC-544-induced apoptosis in BCP-ALL cells. This is in contrast to studies with the comparable CD33 immunotoxin gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) patients, in which complete and prolonged CD33 saturation was required for apoptosis induction. These data suggest that CMC-544 treatment may result in higher response rates in ALL compared with response rates obtained in AML with Mylotarg, and that therefore clinical studies in ALL, preferably with multiple low CMC-544 dosages, are warranted.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children, representing around 30% of cancer diagnoses among children younger than 15 years of age. 1 In the majority of ALL cases (85%), the B-cell precursors are affected (BCP-ALL), while in 15% of cases the malignant cells are of T-cell origin (T-ALL).
2 ALL treatment generally comprises chemotherapy consisting of different combinations of cytostatic drugs depending on the collaborative group protocols. Currently at least 80-85% of childhood ALL patients are cured with conventional chemotherapy, 1, 3, 4 but these drugs may result in several adverse acute and long-term side effects, such as neurocognitive late effects, infertility, secondary malignancies or cardiotoxicity. 5, 6 Therefore, nowadays, new approaches are not only aiming at achieving higher survival rates, but also at diminishing long-term side effects and improving quality of life.
One of these new approaches is antibody (Ab)-targeted chemotherapy, where the Ab-part of the compound is used to specifically deliver the cytostatic drug to the target cell, resulting in less or no bystander cell death. One of the first examples of Abbased delivery is gemtuzumab ozogamicin (GO, Mylotarg or CMA-676), which consists of a humanized CD33 Ab covalently linked to a derivative of the potent DNA-damaging cytotoxic agent calicheamicin. 7, 8 Calicheamicin induces cell death in its target cells by interaction with double-helical DNA in the minor groove causing site-specific double-stranded DNA cleavage at very low concentrations. 9 GO was initially developed for the treatment of patients with CD33-positive acute myeloid leukemia (AML) and the single-agent maximum tolerated dose was two infusions of 9 mg/m 2 with a 14-day interval. Later regimens in combination with chemotherapy usually applied a single dose of GO at a dose of 3-4.5 mg/m 2 . Despite the initial accelerated approval, confirmatory studies failed to demonstrate sufficient benefit and revealed liver toxicity, which led to voluntary withdraw of the market authorization in the United States (http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm216458.htm). In children, however, the risk-benefit ratio may be more promising. 10 Recently, a novel Ab-based therapy has been developed, called inotuzumab ozogamicin or CMC-544, which consists of a humanized CD22 Ab (G5/44, selected because of the highest internalization capacity upon stimulation 11 ) conjugated to a derivative of calicheamicin (CalichDMH). CMC-544 is intended to be studied for the treatment of CD22-positive B-cell malignancies. 12 The human B-lymphocyte-restricted antigen (Ag) CD22 is expressed early in B-cell development from the pro-B-cell stage onwards and persists on B-cells until they differentiate into plasma cells. 13 Mature and immature B-cell malignancies generally express CD22. 14 CMC-544 has already been shown to be effective in B-cell lymphoma cell lines and BCP-ALL cell lines. 12, 15 Moreover, also in murine models, CMC-544 showed strong anti-tumor activity against multiple subcutaneous 11, 12 or systemically disseminated human CD22 þ B-cell lymphoma xenografts. 16 Recently, the first results of a phase I trial with CMC-544 in patients with nonHodgkin's B-cell lymphoma have been published demonstrating that CMC-544 has activity in lymphoma patients, with reversible thrombocytopenia as the main toxicity. 17 In these studies CMC-544 was administered as single-agent at a dose of 1.8 mg/m 2 with a 28-day interval. We investigated whether CMC-544 is also effective in primary BCP-ALL cells in vitro. Based on the structural homology between CD22 and CD33 receptors (Siglec family) and the similarity of the two immuno-conjugates, we hypothesized that CMC-544 has a similar mechanism of action as GO. In previous GO studies, we showed that prolonged maximal saturation of CD33 Ags on AML cells by GO is required for efficient GO-induced cell death, both in-vitro and in-vivo. Furthermore, a repeated loop of binding of GO, saturation of CD33 Ags, internalization of the complex and renewed expression of CD33 Ags was essential for intracellular accumulation of calicheamicin and for the efficacy of GO. 18, 19 In the clinical trials with GO in AML patients only low dosages of GO were added to the existing AML treatment protocols to assure a reasonable tolerability of the combination of drugs. With these low concentrations the criteria of prolonged and maximal saturation will not be fulfilled, which might in part explain the low response rates observed in these clinical trials. Moreover, it was shown that AML cells may be relatively resistant to the cytotoxic compound calicheamicin. 20 In this study, we evaluated which parameters determine the efficacy of CMC-544 in vitro in primary BCP-ALL. These data can be taken into account for the design of a clinical phase I/II trial with CMC-544 in children with relapsed BCP-ALL.
Materials and methods

Cells and culture conditions
All human ALL cell lines (MIK-ALL, ALL-P0, REH, RCH-ACV and 697) used were obtained from the German Collection of Microorganisms and Cell cultures (Prof Dr HG Drexler, DSMZ GmbH, Braunschweig, Germany). Cell lines were cultured in RPMI (Lonza, Basel, Switzerland) supplemented with 10% fetal calf serum, penicillin G sodium (100 U/ml) and streptomycin sulfate (0.1 mg/ml), at 37 1C in a humidified atmosphere containing 5% CO2.
Peripheral blood and bone marrow (BM) samples from pediatric patients with BCP-ALL (n ¼ 20) or AML (n ¼ 3) were obtained in accordance to the declaration of Helsinki, with the approval of the local Medical Ethics Committee (Erasmus MC, Rotterdam), after patients had given written informed consent. Mononuclear cells were obtained by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density centrifugation of peripheral blood or BM, and cultured as described for cell lines.
We selected BCP-ALL patients based on variable expression levels of CD22 (median fluorescence intensity (MFI) CD22-label: 13-233). Fully negative BCP-ALL are extremely rare, 21 (Supplementary Figure 1) and therefore were not included in this study.
Antibody conjugates
CMC-544, N-acetyl g-calicheamicin dimethyl hydrazide (CalichDMH, inactive form of calicheamicin), GO and G5/44 Ab were kindly provided by Pfizer Inc. (New York, NY, USA). CMC-544 is comprised of a humanized IgG4 CD22 mAb (G5/44), linked to N-acetyl g-calicheamicin dimethyl hydrazide (CalichDMH) via an acid-labile AcBut linker with an average drug loading of 73 mg of CalichDMH per mg of G5/44 protein (B6 mol/mol). 12 Concentrations of CMC-544 and GO are expressed as equivalents of CalichDMH and that of unconjugated Ab are expressed as the quantity of Ab protein, unless indicated else.
CD22 and CD33 expression levels
CD22 and CD33 expression levels were determined by flow cytometry using PE-conjugated G5/44 Ab or PE-or APCconjugated CD22 Ab (clone HCL-1) from BD Biosciences (San José, CA, USA) and PE-conjugated CD33 Ab (clone P67.6) from BD, respectively. Both CD22 antibodies recognize an epitope located in the same CD22 protein domain.
11 CD22 and CD33 expression levels on ALL cells were expressed as CD22 and CD33 ratio, defined as MFI of ALL cells divided by MFI of CD22-or CD33-negative lymphocytes (T and NK cells) from the same patient, respectively.
In vitro incubation of cells with CMC-544, free calicheamicin, GO or G5/44 Ab For continuous-labeling experiments, ALL cells were incubated at a cell concentration of 1 Â 10 6 cells/ml (100 000 cells/well) in a 96-wells flat-bottom microtiter plate with different concentrations of CMC-544 (0-1000 ng/ml), free calicheamicin (0-100 ng/ ml), GO (0-10 000 ng/ml) or G5/44 Ab (0-10 000 ng/ml) at 37 1C for different periods of time (0, 24, 48, 72 or 96 h).
For pulse-labeling experiments, cells were incubated with various concentrations of CMC-544 for 1 h, 6 h or 24 h at 37 1C, after which non-bound CMC-544 was removed by washing the cells twice with RPMI. The cell pellet was suspended in RPMI/ 10% fetal calf serum (1 Â 10 6 cells/ml) and cells were incubated at 37 1C for 48 h.
For determination of internalization and renewed expression, cells were incubated on ice with CMC-544 (5000 ng/ml) for 15 min, after which non-bound CMC-544 was removed by washing the cells twice with ice-cold RPMI. The cell pellet was suspended in RPMI/10% fetal calf serum (1 Â 10 6 cells/ml) and cells were either stored on ice or incubated at 37 1C for 0.5, 1 or 3 h.
Detection of cell survival
Quantitative flow cytometric analysis of absolute numbers of viable cells was performed using a modified carboxyfluorescein diacetate succinimidyl ester-based cytotoxicity assay, as described previously. 22, 23 Target cells were not labeled with carboxyfluorescein diacetate succinimidyl ester, but to distinguish different cell populations in BM-mononuclear cell of ALL patients (malignant B, mature B and non-B-cells) specific antibodies were used, such as CD10, CD19 and CD20 Ab (all purchased from BD BioSciences). AML blasts were gated on the basis of forward/side scatter, and CD45 and CD34 expression. To each tube 10 000 Flow-Count Fluorospheres (Coulter Corporation, Miami, FL, USA) were added, and 2000 beads were acquired, enabling quantitative analysis of surviving target cells. 7-amino-actinomycin D (Alexis Corp, Lausen, Switzerland) or propidium iodide (Sigma-Aldrich, St. Louis, MO, USA) was used to exclude dead cells.
The percentage of survival was defined as ((mean absolute number of viable target cells in control mediumÀ absolute number of viable target cells (experimental))/(mean absolute number of viable target cells in control medium)) Â 100. Normalized dose-response curves were determined by non-linear regression analysis (Graphpad software, La Jolla, CA, USA), and from these curves IC 50 values (defined as the concentration resulting in 50% survival) were calculated. If no curve could be calculated, data were expressed as 4the highest concentration of the test. Moreover, if less than 300 viable cells were left after culturing of cells in medium, samples were excluded from the analysis.
As a control for the flow cytometric assay, for some patients, also an MTT-based assay was performed, as described previously. 24 Both methods yielded highly comparable results (for CMC-544: Spearmann's correlation coefficient ¼ 0.85; P ¼ 0.02; data not shown).
Detection of double-strand DNA breaks
After exposure of cells for 24 h to various concentrations of CMC-544, cytospin slides were made (50 000 cells per slide). Calicheamicin is known to induce DNA double strand breaks. 9 Histone H2AX is rapidly phosphorylated at serine 139 in the chromatin micro-environment surrounding a double strand break. 25 Analysis of g-H2AX foci was performed as described previously, 26 using monoclonal mouse anti-phospho-histone H2A.X Ab (2 ng/ml; Upstate Biotechnology, Waltham, MA, USA) and FITC-conjugated rabbit anti-mouse (1:40) secondary antibodies (DAKO, Glostrup, Denmark). Cell nuclei were stained with DAPI (Sigma). g-H2AX foci were analyzed under a Zeiss Axioplan fluorescence microscope, and analyzed by Axiovision software (Zeiss, Gö ttingen, Germany).
Cell cycle analysis
For cell cycle analysis, cells were washed with phosphatebuffered saline, fixed and permeabilized for 10 min at room temperature using FACS lysing solution (BD BioSciences). Cells were stained for 30 min at 4 1C with FITC-conjugated anti-Ki-67 monoclonal antibodies (1:10; Zebra Bioscience B.V/DAKO). After washing, cells were incubated with RNase (20 mg/ml; Sigma-Aldrich) for 5 min at 37 1C, and finally stained with 50 mg/ml propidium iodide. Cells were subjected to flow cytometric analysis of DNA content using a FACSCalibur flow cytometer (BD BioSciences). The percentages of cell cycle distribution were calculated by CellQuest software (BD BioSciences).
Detection of apoptosis
Apoptosis was analyzed by labeling the cells with annexin V-FITC and propidium iodide, using the IQP apoptosis kit (ImmunoQuality Products, Groningen, The Netherlands) according to the manufacturer's instructions.
Analysis of CD22 Ag saturation, internalization of CMC-544 and renewed expression of CD22 Ags
Analysis of CD22 saturation, internalization and renewed expression was performed using a flow cytometric assay as described previously for GO. 19 Briefly, to determine the amount of CD22 Ags bound by CMC-544 (CMC-544-bound CD22) cells were incubated with biotin-conjugated mouse anti-human IgG4 antibodies (BD BioSciences), followed by streptavidin-PE (BD BioSciences) as a second step reagent. To detect total CD22 expression (that is, maximal CMC-544 binding), cells were first incubated with excess CMC-544 (final concentration: 5 mg/ml), followed by successive incubation with biotin-conjugated mouse anti-human IgG4 antibodies and streptavidin-PE. As a negative control, cells were incubated with streptavidin-PE alone. To detect CD22 antigenic sites not occupied by CMC-544, cells were incubated with CD22-PE (clone G5/44) or, as a negative control, IgG1-PE (BD Biosciences). Analysis was performed on ALL blast cells, as defined by scatter characteristics and CD10 and/or CD19 expression levels. All incubations were performed at 4 1C to prevent internalization during immunostaining. Data were acquired on a FACSCalibur flow cytometer and analyzed using CellQuest software.
The percentage of saturation was calculated as (specific MFI of CMC-544-bound CD22)/(specific MFI of total CD22 expression) Â 100. In pulse labeling experiments, the percentage of internalization was calculated as [1À(specific MFI of CMC-544-bound CD22 at t ¼ x)/(specific MFI of total CD22 expression at t ¼ 0 h)] Â 100. In pulse labeling experiments, the percentage of renewed CD22 expression was calculated as
No detectable CMC-544 was present in cell supernatants after incubation of CMC-labeled cells at 37 1C (data not shown), assuring that all the CMC-544 that disappears from the cell membrane has been internalized, and has not been dissociated from the cell membrane into the culture medium.
Confocal laser microscopy
MIK-ALL cells were stained with either G5/44-PE or CD22-APC (HCL-1, BD) for 20 min on ice. Cells were washed (cold) and either directly fixed (15 min at RT in PFA 0.5%) or incubated for various times at 37 1C and subsequently fixed. After washing with phosphate-buffered saline/BSA cytospin slides (50 000 cells/slide) were prepared. Cells were embedded in Prolong Gold (Invitrogen, Breda, The Netherlands) supplemented with DAPI (Sigma). The suspension preparations were analyzed on a Leica SP5 laser-scanning confocal microscope (Leica Microsystems BV, Rijswijk, The Netherlands). Analysis was performed using Leica Application Suite (LAS) AF Lite software (Leica Microsystems).
Lysotracker Red DND-99 (Invitrogen-Molecular Probes, Paisley, UK) was used as a lysosomal marker 27 according to the manufacturer's instructions.
Statistics
The nonparametric Mann-Whitney U-test was used to determine differences in sensitivity between AML and ALL cells. Wilcoxon paired t-tests were applied to compare ALL and normal cell fractions within one ALL patient. Pearson's correlation test was used to calculate the strength of linear dependence between different parameters and the efficacy of CMC-544. In all tests, a P-value of less than 0.05 was considered significant.
Results
Mechanism of CMC-544-induced cell death in ALL cell lines
CMC-544-induced dose-and time-dependent cell death in various ALL cell lines, with IC 50 values ranging from 0.15 to 4.9 ng/ml (in calicheamicin equivalents; Figure 1a and Supplementary Figure 2 ). CMC-544-induced cell death was CD22-dependent, as excess G5/44 (the Ab part of CMC-544) blocked CMC-544-induced cell death (Figure 1b) . Incubations with G5/ 44 Ab alone did not affect cell survival (Figure 1c) indicating that CMC-544-induced cell death is not mediated via CD22 signaling.
After binding of CMC-544 to CD22 Ags at the cell surface (Figure 2a) , internalization of the CD22 receptor/CMC-544 complex takes place. Within 30 min after binding, virtually all CD22 antibodies were relocated to the cytoplasm of the cell (Figure 2b ), illustrating rapid internalization of the CD22 Ag/Ab complex. This is followed by fusion of the CMC-544-containing endosome with a lysosome (Figure 2c, yellow) , resulting in a lower internal pH of the vesicle, subsequent degradation of the acid-labile linker between G5/44 Ab and calicheamicin, and release of calicheamicin.
We next examined the actual execution pathway induced by released and activated calicheamicin. After 24 h of incubation, CMC-544 already induced a few ds DNA breaks at a concentration of 10 ng/ml, but severe DNA damage was observed at concentrations of 100 ng/ml or higher (Figure 2d ).
After DNA damage is detected, the cell will try to repair its DNA damage during the G 2 phase of the cell cycle. In rapidly dividing ALL cell lines, a concentration dependent G 2 /M cell cycle arrest was observed after 24 h exposure to 10 or 100 ng/ml CMC-544 (data not shown). Finally, ALL cells became apoptotic (Figure 2e ).
Impact of intracellular accumulation of calicheamicin on efficacy of CMC-544 in ALL cell lines
We previously showed that accumulation of intracellular levels of calicheamicin by a continuous loop of binding/internalization of GO and renewed expression of CD33 Ags highly contributed to the efficacy of GO in AML cells. 18, 19 Prolonged maximal saturation of CD33 Ags by GO was crucial to obtain sufficiently high intracellular GO levels. To investigate whether this was also the case for CMC-544, we first examined the relationship 
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between CMC-544 concentration and saturation of CD22 Ags in various ALL cell lines. Saturation was dependent on CMC-544 concentration, but not on CD22 expression, as cell lines with differential CD22 expression showed a similar relationship between concentration and saturation. By combining the concentration-saturation data with the concentration-survival data (Figure 1a) , the relation between saturation and cell survival could be calculated. As shown in Figure 3a , efficient cell death could already be observed at low CD22-saturation levels, indicating that, in contrast to previous results with GO, no prolonged and maximal saturation is required. To further investigate whether intracellular accumulation of calicheamicin affects the efficiency of CMC-544-induced cell death, we exposed MIK-ALL cells (CD22 high ) and ALL-P0 cells (CD22 low ), both showing equal sensitivity to free calicheamicin (data not shown), either continuously (48 h) or for 1, 6 or 24 h to various concentrations of CMC-544, and measured cell survival after 48 h. In both cell lines, but especially in the CD22 low ALL-P0 cells, continuous exposure to CMC-544 was more effective than pulse exposure (Figures 3b and c) , suggesting that a continuous loop of internalization and renewed expression of CD22 contributes to the efficacy of CMC-544, especially in cells with low CD22 expression. Preliminary data suggest that rapid renewed CD22 expression is due to the presence of an intracellular pool of CD22 receptors (data not shown).
These data collectively show that only a limited amount of calicheamicin is required to induce cell death, but that intracellular accumulation of calicheamicin by continuous internalization and renewed expression potentiates CMC-544 efficacy and leads to more rapid and efficient cell death.
Effect of CMC-544 on cell survival of primary ALL and various CD22-negative cells
To investigate whether CMC-544 is also effective in primary BCP-ALL cells, BM-mononuclear cells from 20 patients with BCP-ALL with variable CD22 expression (CD22 ratio ranging from 2.5. to 26.4) were tested for their sensitivity to CMC-544, as shown for one ALL patient sample in Figure 4a . Patient data are summarized in Supplementary Table 1. CMC-544 induced both dose-dependent and time-dependent cell death in primary ALL cells (Figure 4b ). IC 50 values of ALL cells (CD10 þ CD19 þ ) varied enormously (Figure 4c ), but were generally B1000-fold lower than IC 50 values of normal cells (CD10 À CD19 À CD22 À , mainly T-cells) derived from the same patients (median IC 50 values of 4.8 and 2928 ng/ml calicheamicin equivalents, respectively). To further define the specificity of CMC-544, five BCP-ALL and three AML patient samples were exposed to free calicheamicin, CMC-544 and GO (Supplementary Figure 3) . AML patient cells were equally sensitive to calicheamicin and GO, and the least sensitive to CMC-544. Primary BCP-ALL cells were over 1000 times as sensitive to calicheamicin as primary AML cells, and B100 times as sensitive to CMC-544. ALL patient cells were more sensitive to CMC-544 than to GO, demonstrating CD22-specific uptake of CMC-544.
Important parameters for efficacy of CMC-544
To unravel the heterogeneity in sensitivity of ALL blasts to CMC-544, we examined which parameters are important for efficient CMC-induced cell death, based on the mechanism of action presented before.
Sensitivity to calicheamicin. We first analyzed the sensitivity of ALL cells to free calicheamicin. Similar to IC 50 values for CMC-544, IC 50 values for calicheamicin varied substantially between different ALL patients (Figure 5a) . A strong correlation (r ¼ 0.8, P ¼ 0.0004) was found between sensitivity to calicheamicin and efficacy of CMC-544, indicating that efficacy of CMC-544 is highly dependent on cellular sensitivity towards calicheamicin. In line with previous studies, 20 primary ALL cells (n ¼ 20) were significantly more sensitive to calicheamicin (median: 0.17 ng/ml) than primary AML cells (n ¼ 3, median: 1023 ng/ml; Figure 5b ), suggesting that lower intracellular concentrations may already be effective in ALL compared with AML cells. Efficacy of CMC-544 in BCP-ALL JF de Vries et al CD22 expression. In primary ALL cells, no direct relation was found between CD22 expression and efficacy of CMC-544 (Figure 6a ), probably owing to the predominant contribution of calicheamicin sensitivity to CMC-544-induced cell kill. The difference in sensitivity for CMC-544 and calicheamicin (that is, the ratio between the IC 50 for calicheamicin and the IC 50 value for CMC-544) was only weakly related to CD22 expression levels (Figure 6b ), (r 2 ¼ 0.21; P ¼ 0.09). Therefore, although CD22 expression is required for CMC-544 binding and internalization, CD22 levels apparently have only a minor role in determining CMC-544 efficacy.
Internalization of CMC-544. We next studied whether the rate of internalization of CMC-544 contributes to CMC-544 efficacy. A significant correlation was found between internalization and efficacy of CMC-544 (Figure 6c) . Moreover, two patients who were relatively insensitive to CMC-544 (IC 50 values 41000 ng/ml after 48 h), showed the lowest internalization capacity. Interestingly, for one of these patients (with an internalization of 60%), CMC-induced cell death was only delayed, since after 96 h of exposure less than 50% leukemic cell survival was observed.
Renewed expression of CD22 Ags. As renewed expression of CD22 Ags at the cell surface may result in an ongoing process of saturation, internalization and consequently in an ongoing intracellular accumulation of calicheamicin, we evaluated whether renewed CD22 expression was related to sensitivity to CMC-544. As shown in Figure 6d , no relation was observed between both parameters.
Altogether, these data show that the efficacy of CMC-544 in primary ALL cells is mainly dependent on the cellular sensitivity to calicheamicin, and to a lesser extent on CD22/CMC-544 internalization, whereas CD22 expression levels and renewed expression do not seem to contribute significantly.
Discussion
This study demonstrates that CMC-544 effectively kills primary CD22 þ BCP-ALL cells in vitro. The proposed mechanism of action of CMC-544 is highly comparable to the CD33 immunotoxin GO, involving binding of CMC-544 to CD22 Ags, internalization of the CD22/CMC-544 complex, fusion of the CMC-544 containing endosome with a lysosome, release of calicheamicin, induction of ds DNA breaks (frequently leading to G 2 /M cell cycle arrest) and finally induction of apoptosis ( Figure 7) . However, in this study we also demonstrate that major differences exist between GO in AML and CMC-544 in ALL, which may have impact on the clinical development of these compounds. Particularly, the high sensitivity of ALL cells for CMC-544 and calicheamicin will allow specific and efficient killing of ALL cells at relatively low dosages.
A major finding of our studies is that the intracellular threshold of calicheamicin required for cell death induction is much easier reached in BCP-ALL cells (with CMC-544) than in AML cells (using GO). The intracellular threshold level is dependent on at least three processes. First, calicheamicin needs to be targeted to the cells by binding of CMC-544 to the CD22 Ag and subsequent internalization of the CMC-544/CD22 Ag complex. Second, intracellular calicheamicin can be pumped out of the cell by various drug efflux pumps. Finally, the intracellular threshold level is dependent on the intrinsic sensitivity of the target cell for calicheamicin. Although expression of drug efflux pumps like P-glycoprotein (Pgp) 28 and MRP 29 may have a major role in the unresponsiveness of adult patients to GO 30 and CMC-544, 31 drug efflux does not seem to be a general problem in pediatric ALL. [32] [33] [34] Consequently, the intracellular accumulation of calicheamicin in ALL cells is mainly dependent on the binding and internalization of CMC-544. In line with this, the sensitivity of BCP-ALL cells to CMC-544 was mainly determined by the cell's sensitivity to calicheamicin. Although CD22 expression was essential for CMC-544 binding and internalization, a repetitive loop of CD22 saturation, CD22/CMC-544 internalization and renewed CD22 expression was not required to achieve intracellular threshold levels of calicheamicin sufficient for efficient CMC-544-induced apoptosis in BCP-ALL cells. Nevertheless, high CD22 expression levels may accelerate CMC-544-induced cell death. Especially in CD22 low ALL cells ongoing CD22/CMC-544 binding and internalization and renewed CD22 expression contributed to the efficacy of CMC-544, as demonstrated by the higher efficacy of CMC-544 after continuous (48 h) than after pulse (1, 6 or 24 h) exposure. Apparently, in CD22 low ALL cells it takes longer before intracellular threshold levels of calicheamicin are obtained after exposure to CMC-544. This was further illustrated by the finding that in ALL-P0 (CD22 low ), but not in MIK-ALL (CD22 high ), cells after 24 h of incubation, a difference in efficacy between free calicheamicin and CMC-544 was observed, whereas no difference was found anymore after 72 h of incubation (data not shown), showing that CMC-544-induced cell death was only delayed in CD22 low ALL cells. These data are in clear contrast to studies with GO in AML patients, in which complete and prolonged CD33 saturation was required for apoptosis induction, which may be related to a high drug efflux of AML cells and reduced calicheamicin sensitivity. 30 Although CD22 expression is required for CMC-544's activity, in primary BCP-ALL cells the efficacy of CMC-544 was not dependent on CD22 expression levels, as no significant correlation was found between these two parameters. Apparently, even low CD22 expression levels can already result in sufficiently high intracellular calicheamicin levels. In addition, CD22-independent uptake of CMC-544 by ALL cells may contribute to its cytotoxic effect, in a similar way as we published previously for CD33-independent endocytosis of GO by BCP-ALL cells. 35 Our data indicate that CMC-544-induced cell death was completely mediated via calicheamicin-induced apoptosis and not by CD22 signaling. This is in contrast to GO, where expression of the protein kinase Syk was essential for efficacy of GO in AML cells, suggesting that CD33 signaling contributed to GO-induced cell death. 36 For future clinical trials with CMC-544, preferably CD22-positive patients should be included, but our data suggest that the level of CD22 expression does not need to be taken into account (although high CD22 expression on ALL cells will enhance/facilitate CMC-544-induced cell death). However, given the CD22-independent uptake of CMC-544, it may be interesting to evaluate the in vivo efficacy of CMC-544 in CD22-negative ALL patients as well.
Although CD22 expression levels only limitedly affect CMC-544 efficacy, the capacity of internalization of the CD22/CMC-544 complex was important for CMC-544 efficacy. Two patients showed ineffective internalization after 3 h (Figure 6c ), which was accompanied by ineffective CMC-544 response. One of these patients only showed a delayed CMC-544 response, whereas the other was resistant. As the latter patient was also resistant to calicheamicin, it is difficult to determine the contribution of inefficient internalization to the CMC-544 resistance. Comparable to the differential internalization of Rituximab in certain subgroups of mature B-cell lymphomas, 37 BCP-ALL subgroups with differential internalization of CMC-544 may exist. However, the strong relation between CMC-544 sensitivity and calicheamicin sensitivity indicates that the uptake of CMC-544 (including binding, internalization, and renewed expression) is generally not limiting the efficacy of CMC-544. This is in contrast to GO in AML patients, in which the efficacy of GO is highly dependent on the intracellular accumulation of GO via the ongoing process of saturation, internalization and renewed expression of CD33. 18, 19 Consequently, a positive correlation was found between CD33 expression and the efficacy of GO. 38 Goemans et al., 39 previously postulated that the large interpatient differences in calicheamicin efficacy in pediatric AML are caused by differences in intrinsic sensitivity of these target cells to calicheamicin. Similarly, the heterogeneity in response to calicheamicin in BCP-ALL cells may also be explained by differences in intrinsic calicheamicin sensitivity, which is dependent on the level of DNA accessibility, DNA repair capacity or functionality of the apoptotic machinery (expression of pro-and anti-apoptotic proteins) of the target cells. Decreased DNA accessibility had a role in GO efficacy, as addition of valproic acid, an agent causing histone hyperacetylation that opens the chromatin structure, had a beneficial effect on GO-induced cell death in AML patients. 40 We are currently investigating whether these mechanisms have a role in CMC-544 efficacy as well.
To confirm our in-vitro results, clinical studies with CMC-544 in BCP-ALL patients are warranted. As shown in previous clinical trials with GO in AML patients, consumption of GO by circulating peripheral CD33 þ cells affected GO concentrations within the BM, thereby hampering the efficacy of GO. These problems could be partially solved by administration of multiple dosages of GO and by erasing the leukemic burden by chemotherapy before infusion of GO. 41 We expect that circulating CD22 þ cells will only limitedly hamper the efficacy of CMC-544 in ALL patients, as no complete saturation of CD22 Ags on ALL cells in the BM is required to obtain efficient CMC-544-induced cell death.
In conclusion, most of the drawbacks with GO in AML likely can be avoided for CMC-544 treatment in BCP-ALL patients. Our data suggest that clinical efficacy may be obtained even when smaller dosages are given in combination with chemotherapy, and that, for instance, a fractionated schedule during a typical 4-week ALL-induction regimen may be effective, rather than a single-agent high-dose regimen. Therefore, although in the just started clinical trial of CMC-544 in adult ALL CMC-544 is given as one single high dosage (1.8 mg/m 2 ) per 4-week cycle (NCT01134575), other clinical studies will be performed applying repetitive low dosages of CMC-544, which can later be easily combined with existing multi-agent chemotherapy regimens.
